Application YC di GEn1E Lifesciences
GEn1E Lifesciences ha partecipato a Y Combinator nel batch Summer 2019 come azienda Healthcare. Sotto: cosa fa l'azienda, chi l'ha fondata e la sua application a YC, ricostruita domanda per domanda nel form reale di YC.
- Batch YC
- Summer 2019
- Settore
- HealthcareTherapeutics
- Stato
- Active
- Lanciata
- 2022
Founder
Ritu LalFounder
Cosa fa GEn1E Lifesciences
GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. We develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. Our team is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities - creating novel therapeutics at an unprecedented pace. Our AI platform has enabled us to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Our AI platform enables tremendous pace and capital efficiency as demonstrated by our progress in ~2 years with seed capital - a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. The team at GEn1E has decades of experience in drug development and machine learning. We graduated from YCombinator and Stanford-StartX in late 2019. We are based in Palo Alto, CA.
Application YC di GEn1E Lifesciences, ricostruita
Domanda per Y Combinator
GEn1E Lifesciences, batch Summer 2019. Le vere domande del form, risposte da dati pubblici.
- Founders2
- Company7
- Progress7
- Idea4
- Equity3
- Curious2
- Batch Preference1
Company
GEn1E Lifesciences
AI platform accelerating therapies for rare diseases
We are building an AI platform that speeds up discovery and development of novel immunomodulatory therapies targeting multiple mechanisms at once. Our platform identifies and optimizes protein therapies for rare and inflammatory diseases with no current treatments. We've already developed a lead candidate for ARDS and a pipeline of 21+ selective immunomodulators.
We live in Palo Alto, CA, and the company is based here.
Palo Alto puts us at the center of biotech and AI innovation, with access to top talent, investors, and collaborators. It's also where we're rooted personally and professionally.
21 risposte in più nell'application completa
Founders, Progress, Idea, Equity, Curious, Batch Preference sono nella versione completa. Crea un account gratuito per aprirla in YC Insights, accanto a ogni altro batch YC.
Domande Frequenti
Questa è l'application YC reale di GEn1E Lifesciences?
No. Y Combinator mantiene private le application inviate. Questa è una ricostruzione: le domande del form YC reale, a cui si è risposto usando i dati pubblici di GEn1E Lifesciences (note di lancio, background dei founder, descrizione del prodotto). Mostra come un'azienda come GEn1E Lifesciences si presenterebbe a YC, non il testo che hanno inviato.
A quale batch YC apparteneva GEn1E Lifesciences?
GEn1E Lifesciences apparteneva al batch Summer 2019 di Y Combinator.
Chi ha fondato GEn1E Lifesciences?
GEn1E Lifesciences è stato fondato da Ritu Lal.
Cosa fa GEn1E Lifesciences?
AI platform accelerating therapies for rare & inflammatory diseases.
Come leggo la ricostruzione completa della application?
Crea un account Round Funded gratuito. La versione completa di 26 risposte della application di GEn1E Lifesciences, e di ogni altro batch YC, è in YC Insights.
Più startup YC come GEn1E Lifesciences
